



30th September, 2009

Marketing Approval for Paraldehyde Injection

Phebra announced today that Paraldehyde Injection has been granted marketing approval in Australia.

Paraldehyde Injection is used as a sedative and hypnotic for the treatment of convulsive episodes arising from tetanus, status epilepticus and poisoning by convulsive drugs, when other agents are inappropriate or ineffective. It can also be used to manage the anxiety associated with narcotic or barbiturate withdrawal or delirium tremens due to alcohol withdrawal.

“Paraldehyde is a critical medicine that has an important role in the treatment of a variety of clinical situations that are difficult to manage with standard therapies”, said Dr Mal Eutick, CEO of Phebra, “we have been making Paraldehyde Injection available to the Australian market as an unapproved medicine and are very pleased to have achieved marketing approval in Australia, which will streamline its availability”.

Paraldehyde Injection is now available to wholesalers and Australian hospitals.

Phebra is an Australian based specialty pharmaceutical company that develops and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe. For more information about Phebra please refer to the company website at www.phebra.com.

At Phebra, we create critical medicines that save and improve lives.